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Friedrichsen M, Birk JB, Richter EA, Ribel-Madsen R, Peh-
møller C, Hansen BF, Beck-Nielsen H, Hirshman MF, Goodyear
LJ, Vaag A, Poulsen P, Wojtaszewski JF. Akt2 influences glycogen
synthase activity in human skeletal muscle through regulation of
NH2-terminal (sites 2  2a) phosphorylation. Am J Physiol Endocri-
nol Metab 67: E631–E639, 2013. First published January 15, 2012;
doi:10.1152/ajpendo.00494.2012.—Type 2 diabetes is characterized
by reduced muscle glycogen synthesis. The key enzyme in this
process, glycogen synthase (GS), is activated via proximal insulin signal-
ing, but the exact molecular events remain unknown. Previously, we dem-
onstrated that phosphorylation of Thr308 on Akt (p-Akt-Thr308), Akt2
activity, and GS activity in muscle were positively associated with
insulin sensitivity. Here, in the same study population, we determined
the influence of several upstream elements in the canonical PI3K
signaling on muscle GS activation. One-hundred eighty-one nondia-
betic twins were examined with the euglycemic hyperinsulinemic
clamp combined with excision of muscle biopsies. Insulin signaling
was evaluated at the levels of the insulin receptor, IRS-1-associated
PI3K (IRS-1-PI3K), Akt, and GS employing activity assays and
phosphospecific Western blotting. The insulin-stimulated GS activity
was positively associated with p-Akt-Thr308 (P  0.01) and Akt2
activity (P  0.04) but not p-Akt-Ser473 or IRS-1-PI3K activity.
Furthermore, p-Akt-Thr308 and Akt2 activity were negatively associ-
ated with NH2-terminal GS phosphorylation (P  0.001 for both),
which in turn was negatively associated with insulin-stimulated GS
activity (P  0.001). We found no association between COOH-
terminal GS phosphorylation and Akt or GS activity. Employing
whole body Akt2-knockout mice, we validated the necessity for Akt2
in insulin-mediated GS activation. However, since insulin did not
affect NH2-terminal phosphorylation in mice, we could not use this
model to validate the observed association between GS NH2-terminal
phosphorylation and Akt activity in humans. In conclusion, our study
suggests that although COOH-terminal dephosphorylation is likely
necessary for GS activation, Akt2-dependent NH2-terminal dephos-
phorylation may be the site for “fine-tuning” insulin-mediated GS
activation in humans.
glycogen synthesis; insulin signaling; muscle; phosphatidylinositol
3-kinase/protein kinase B; diabetes
TYPE 2 DIABETES (T2D) is characterized by reduced insulin-stimulated
glucose uptake, which can be attributed largely to reduced muscle
glycogen synthesis (37). Although glucose uptake/transport is an
important rate-limiting process regulating glycogen synthesis (29,
34), several studies have demonstrated that the activity of the key
enzyme in glycogen synthesis, glycogen synthase (GS), is rate
limiting under various conditions in both animals (1, 8, 26) and
humans (29, 39, 42) as well. Accordingly, it has been estimated
that the “control coefficient” for GS activity in the regulation of
whole body glucose disposal is 30%, underlining the importance
of GS activity in the control of glucose homeostasis (23). Thus, a
thorough understanding of the regulation of this important en-
zyme is crucial to finally elucidate the mechanisms responsible for
insulin-mediated glucose uptake.
The regulation of GS activity is complex and involves
allosteric regulation by glucose 6-phosphate (38) and glycogen
(21) as well as inhibitory phosphorylations of GS. Although
several important phosphorylation sites have been identified,
sites 2 and 2a (NH2 terminus) and 3a and 3b (COOH terminus)
are generally considered the most important for GS activity (6,
26, 38). GS site 2 is phosphorylated by several kinases,
including AMP-activated protein kinase (AMPK) and protein
kinases A (PKA) and C (PKC) (6, 17), allowing for sequential
phosphorylation of site 2a by casein kinase-1 (17). Phosphor-
ylation of sites 3a and 3b on GS (p-GS 3a  3b) is regulated
mainly by GS kinase-3 (GSK-3) (6). Dephosphorylation of GS
may involve protein phosphatase 1 (26, 35) or occur sponta-
neously due to high phosphate turnover in GS (17).
Overall, activation of GS by insulin is believed to involve
the insulin receptor, insulin receptor substrate-1 (IRS-1), phos-
phatidylinositol 3-kinase (PI3K), Akt-dependent inhibition of
GSK-3, and dephosphorylation of sites 3a and 3b (6, 7, 17, 19,
26). Previous studies have demonstrated significant dysregula-
tion of muscle GS activity in insulin-resistant and type 2
diabetic individuals (13, 15, 17–19, 33, 42). However, the
nature and importance of this abnormality is still debated. A
genetic origin of the reduced GS activity in insulin-resistant
individuals has been hypothesized, and although polymor-
phisms in the muscle GS gene have been linked to T2D (14),
we demonstrated previously that GS activity could be attrib-
uted largely to nongenetic regulation (33).
Two studies on the present data have been published previ-
ously. First, we investigated the regulation of proximal insulin
signaling (from insulin receptor to Akt) and its association with
whole body insulin sensitivity (9). Second, we investigated the
heritability of GS activity/phosphorylation and its association
with insulin sensitivity (33). The novel aspect of this study is
to focus on the regulation of GS activity by proximal insulin
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signaling. This was not addressed in our previous studies, and
we are unaware of other data sets allowing such in-depth
association studies of the (currently known) most important
molecular mediators of muscle insulin action. This is the first
major study, including almost 200 participants, to investigate
numerous insulin signaling molecules ranging from the most
proximal to the resulting activation of muscle GS, uniquely
allowing us to differentiate the significance of each step in
proximal insulin signaling on GS activation in humans. Spe-
cifically, we investigated the association between GS activity
and insulin receptor tyrosine kinase (IRTK), IRS-1-associated
PI3K (IRS-1-PI3K), and Akt1 and Akt2 activity as well as
phosphorylation of Thr308 on Akt (p-Akt-Thr308) and Ser473 on
Akt (p-Akt-Ser473).
METHODS
Young (22–31 yr) and old (57–66 yr) monozygotic and same-sex
dizygotic twin pairs (n  98 twin pairs) born at term (3 wk from
expected term) were identified through the Danish Twin Register
(31–33) (Table 1). Zygosity was determined by polymorphic genetic
markers (30). The twin study design facilitated evaluation of the
genetic component in insulin signaling. These data have been reported
previously (9, 33) and thus will not be discussed here. Glucose
tolerance status was defined according to the 1999 World Health
Organization criteria (12). The study population was generally healthy
but included three participants with screen-detected T2D that were
excluded from the analyses to avoid issues with hyperglycemia-
induced alterations of insulin signaling. The study was approved by
the regional ethics committee for the counties of Funen and Vejle,
Denmark, and performed according to the Declaration of Helsinki.
Informed consent was obtained from the study participants.
Clinical examination. Participants underwent a 2-day clinical ex-
amination, including a standard 75-g oral glucose tolerance test,
anthropometric measurements that included weight, height, and waist
and hip circumferences, and determination of body composition by
dual energy X-ray absorptiometry scanning and maximal aerobic
capacity (V˙ O2 max) by bicycle ergometer testing (31–33). Insulin
sensitivity was examined by a 2-h (40 mU·m2·min1) euglycemic
hyperinsulinemic clamp. Insulin levels were 400 pmol/l during
insulin infusion (32). A primed, constant, continuous infusion of
[3-3H]tritiated glucose (bolus 22 Ci, 0.22 Ci/min) was initiated at
0 min and continued throughout the clinical investigation [basal
period (120 min) and clamp period (120 min)]. Steady state (defined
as the last 30 min of the basal and insulin-stimulated periods) was
achieved (32). The glucose disappearance rate during insulin stimu-
lation [glucose disposal (Rd) clamp] was calculated using the non-
steady-state equations by Steele (31). Muscle biopsies (m. vastus
lateralis) were taken during these periods [n  181 individuals (101
young and 80 old)] using a Bergström needle with suction applied.
Biopsies were frozen in liquid nitrogen and stored at 80°C. For a
more elaborate description of the clinical examination, we refer to
previous studies of this study population (31–33).
Transgenic mice analyses. All animal experiments were conducted
in accordance with the guidelines of the Institutional Animal Care and
Use Committee of the Joslin Diabetes Center and the National
Institutes of Health. Four male and two female Akt2 knockout (KO)
and four male and two female wild-type mice on a C57BL/6N
background (10–12 wk of age) (4) were studied. Mice were kept on
a 12:12-h light-dark cycle with ad libitum access to standard chow and
water. After 12–14 h without access to food, extensor digitorum
longus (EDL) muscles were quickly removed from the euthanized
mouse (cervical dislocation) and incubated in Krebs-Henseleit solu-
tion (117 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4,
1.2 mM MgSO4, and 24.6 mM NaHCO3 with addition of 2 mM
pyruvate, pH 7.4) at 37°C and oxygenated with gas containing 95%
O2 and 5% CO2. Incubations were carried out in the presence or
absence of insulin (150 nM, Humulin R, human insulin; Eli Lilly,
Indianapolis, IN). All muscles were preincubated for 10 min follow-
ing dissection and subsequently incubated for 30 min in the presence
or absence of insulin. After incubation, muscles were quickly frozen
in liquid nitrogen and stored at 80°C.
Protein analyses. The methodology for the preparation of lysate for
protein analyses has been described previously (10). In brief, 50 mg of
muscle was homogenized (Polytron PT 3100; Kinematica) in a buffer
[1:20 (wt/vol)] containing 50 mM HEPES (pH 7.5), 150 mM NaCl, 20
mM Na-pyrophosphate, 20 mM -glycerophosphate, 10 mM NaF, 2
mM Na-ortovanadate, 2 mM EDTA, 1% Nonidet P-40, 10% glycerol,
2 mM PMSF, 1 mM MgCl2, 1 mM CaCl2, 10 g/ml leupeptin, 10
g/ml aprotinin, and 3 mM benzamindine. Homogenates were rotated
end over end for 1 h (4°C) and cleared by centrifugation at 17,500 g
Table 1. Clinical characteristics and insulin signaling
parameters
Clinical Characteristic and Insulin
Signaling Parameter Means (SD)
Zygosity (MZ/DZ) 101/80
Age, yr 43 (17)
Birth weight, g 2,640 (480)
BMI, kg/m2 25 (3.8)
Total fat, % 24.5 (8.6)
V˙ O2max, ml  min1  kg1 34.1 (9.8)
Rd clamp, mg  kg fat-free mass1  min1 11.0 (3.4)
Glycogen content, basal (mmol/kg wet wt muscle 89.4 (24.3)
Glycogen content, insulin stimulated, mmol/kg wet wt
muscle
89.0 (24.4)
IRTK (AU) 4.5 (1.9)
IRS-1-PI3K (AU) 54.3 (33.6)
p-Akt-Thr308 (AU) 35.6 (21.9)
p-Akt-Ser473 (AU) 40.7 (22.7)
Akt1 activity, fmol  min1  mg protein1 52.9 (32.4)
Akt2 activity, fmol  min1  mg protein1 71.8 (38.9)
p-GS 2  2a, basal (AU) 3.8 (2.7)
p-GS 2  2a, insulin stimulated (AU) 3.1 (2.0)*
p-GS 3a  3b, basal (AU) 0.26 (0.19)
p-GS 3a  3b, insulin stimulated (AU) 0.16 (0.10)*
GSK-3 activity, basal, nmol  min1  mg protein1 5.1 (1.1)
GSK-3 activity, insulin stimulated, nmol  min1  mg
protein1
3.6 (0.9)*
GS activity, basal, 0.17 mmol/l G6P, nmol  min1  mg
wet wt muscle1
0.8 (0.3)
GS activity, basal, 8.00 mmol/l G6P, nmol  min1  mg
wet wt muscle1
4.6 (1.1)
GS activity, basal (FV%) 16.6 (6.0)
GS activity, insulin, 0.17 mmol/l G6P, nmol  min1  mg
wet wt muscle1
1.5 (0.6)*
GS activity, insulin, 8.00 mmol/l G6P, nmol  min1  mg
wet wt muscle1
4.6 (1.1)
GS activity, insulin stimulated (FV%) 32.6 (9.5)*
	-GS activity (FV%) 15.9 (6.7)
Data are means (SD); n  181 (93 males and 88 females). MZ, monozy-
gotic; DZ, dizygotic; Rd clamp, rate of glucose infusion during the euglycemic
hyperinsulinemic clamp; IRTK, insulin receptor tyrosine kinase; IRS-1-PI3K,
insulin receptor substrate-1-associated phosphatidylinositol 3-kinase; p-Akt-
Ser473, phosphorylation of Ser473 on Akt; p-Akt-Thr308, phosphorylation of
Thr308 on Akt; GS, glycogen synthase; AU, arbitrary units; p-GS 2  2a,
phosphorylation of sites 2 2a on GS; p-GS 3a 3b, phosphorylation of sites
3a  3b on GS; %FV, %fractional velocity; 	-GS activity, insulin-mediated
increase in GS fractional activity; G6P, glucose 6-phosphate. Only insulin-
stimulated protein activities/phosphorylations are stated, unless otherwise
indicated. GS phosphorylation was corrected for total GS protein content.
Since the antibodies for total Akt protein and phosphorylation status were not
isoform specific, this could not be done for Akt phosphorylation. For basal
levels of protein activities/phosphorylations of IRTK and IRS-1-PI3K, please
see previous studies of this study population (9). *P 0.0001 vs. basal values.
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for 1 h (4°C). The lysate was stored at 80°C for later analysis. All
chemicals were obtained from Sigma-Aldrich (St. Louis, MO). Pro-
tein content was determined by the bicinchoninic acid assay (Pierce,
Rockford, IL).
IRTK activity was measured in muscle lysate after immunopurifi-
cation of the insulin receptor (anti-IR, AB3; Oncogen Science), using
a microtiter assay as described previously (44). IRS-1-associated
PI3K activity was measured in muscle lysate after immunopurification
of IRS-1 (anti-IRS-1, no. 06-248; Upstate Biotechnology), as de-
scribed previously (19). Sequential immunopurification of Akt2 (anti-
Akt2, no. 06-606; Upstate Biotechnology) and then Akt1 (anti-Akt1,
no. 06-558; Upstate Biotechnology) was performed on 400 g of
muscle lysate before Akt activity measurements. Prior depletion of
Akt2 protein was important to avoid coimmunopurification of Akt1 as
well as Akt2 using the anti-Akt1 antibody. The immunopurification
was performed employing G-Sepharose beads. The pellet was washed
three times in a buffer containing 20 mmol/l Tris (pH 7.4), 5 mmol/l
EDTA, 10 mmol/l Na4P2O7, 100 mmol/l NaF, 1% NP-40, and 3
mmol/l Na3VO4 and twice in a buffer containing 20 mmol/l Tris (pH
7.4), 10 mmol/l MgCl2, and 1 mmol/l dithiothreitol. The kinase
activity assay was performed in a buffer containing 50 mmol/l Tris
(pH 7.4), 10 mmol/l MgCl2, 1 mmol/l dithiothreitol, and 1 mol/l
protein kinase inhibitor (no. P-0300; Sigma-Aldrich) employing 30
mol/l Akt/SGK substrate peptide (no. 12-340; Upstate Biotechnol-
ogy) and [
-32P]ATP (111 kBq/sample; Perkin-Elmer, Boston, MA)
as substrates. The kinase assay ran for 30 min at 30°C before the
reaction was stopped by the addition of a buffer containing 0.6% HCl,
1 mmol/l ATP, and 1% BSA. Akt and GS phosphorylation status was
evaluated by Western blotting [see Højlund et al. (20) for a detailed
description] with phospho- and site-specific antibodies raised against
p-Akt-Thr308 (no. 06-678; Upstate Biotechnology), p-Akt-Ser473
(9271; Cell Signaling Technology, Beverly, MA), p-GS 2  2a
(phosphorylation of Ser7 and Ser10), and p-GS 3a  3b (phosphory-
lation of Ser640 and Ser644). The antibodies raised against p-GS 2 
2a and p-GS 3a  3b were a gift from Prof. Grahame D. Hardie
(Division of Molecular Physiology, University of Dundee, Dundee,
UK). GS phosphorylation was corrected for total GS protein content.
This could not be done for Akt phosphorylation since the antibodies
for total Akt protein and phosphorylation status were not isoform
specific. Furthermore, only insulin-stimulated measurements of prox-
imal insulin signaling were used, since basal Akt1 and Akt2 activity
as well as p-Akt-Thr308 could not be reliably determined; e.g.,
measurement of basal Akt2 activities in a subpopulation of 43 indi-
viduals provided paradoxical negative activity values for more than
one-third of the basal samples. To obtain a rough estimate of the effect
of insulin on Akt2 activity, we employed these measurements for
basal Akt2 activity and found that insulin stimulation resulted in
approximately fourfold increased Akt2 activity. However, due to the
uncertainties associated with these measurements, these data will not
be discussed further in this article. For GSK-3 activity measure-
ments, GSK-3 was immunoprecipitated from lysate using an anti-
GSK-3 antibody (no. 06-391; Upstate Biotechnology) bound to
protein G-Sepharose. Kinase activity was measured as described
previously (20). GS activity in the presence of 0.17 or 8 mmol/l
glucose 6-phosphate was measured in duplicate, employing a 96-well
plate assay (Unifilter 350 plates; Whatman, Cambridge, UK) (19). GS
activity is given as the fractional activity (100  activity at 0.17 mmol/l
glucose 6-phosphate activity at 8 mmol/l glucose 6-phosphate). Both
the absolute insulin-stimulated values and the insulin-mediated in-
crease of (insulin-stimulated GS activity  basal GS activity, 	) GS
fractional activity were used as measurements of GS activity. Glyco-
gen content was determined as glycosyl units after acid hydrolysis, as
described previously (43). Protein activity/phosphorylation status was
related to a standard loaded on each gel/assay, allowing for compar-
ison between different gels/assays.
Statistics. All statistical tests were performed employing SAS
statistical software (SAS Institute, Cary, NC), using the proc mixed
procedure (multiple linear regression) to adjust for twin pair and
zygosity status and other contributing variables, including age, sex,
V˙ O2 max, total fat percentage, and basal glycogen content. A statistical
model to test the association between GS activity and Akt2 activity
looks like this: ln(insulin-stimulated GS activity)  age  sex  total
fat percentageV˙ O2 max basal glycogen contentAkt2 activity. The
model calculates an estimate for the -coefficients (with corresponding P
values) of each explanatory variable. These estimates for the -coeffi-
cients represent the increase/decrease in the response variable associated
with an increase of the explanatory variable of one unit (e.g., 1 unit of fat
percentage from 24 to 25%). In the statistical model employed throughout
this study, we had to log transform the response variables (e.g., GS
activity) to avoid skewness of the residuals (a normal distribution of
residuals is a prerequisite for the statistical model). This log transforma-
tion resulted in estimates expressing percentage-wise and not absolute
changes of the response variable. Since activity/phosphorylation of pro-
teins in the insulin signaling cascade was measured in arbitrary units with
no direct physiological relevance, the association between the explana-
tory variables and the response variables in Table 2 was calculated per
doubling of the explanatory variable from the average (e.g., what per-
centage of GS activity increased/decreased when Akt2 activity was
doubled?). A doubling of protein activity/phosphorylation was generally
within 2.5 SD (Table 1) and was thus biologically/statistically possible. In
the mouse study, the data were analyzed employing a repeated two-way
ANOVA (the data were paired with both basal and insulin-stimulated
samples coming from the same mouse; n  6 wild-type and 6 Akt2 KO
mice). If the interaction or a main effect was significant, we examined the
possible differences, employing paired and unpaired t-tests where appro-
priate.
RESULTS
The clinical characteristics of our human population have
been described previously in detail (9, 31–33) and are summa-
rized in Table 1. We have demonstrated previously that GS
activity was positively correlated with whole body insulin
sensitivity in this population (33). To illustrate GS’s potential
effect on glucose metabolism, we calculated the effect sizes
using the statistical model described in METHODS. We found that
a doubling of insulin-stimulated GS activity was associated
with a 47% increased insulin-stimulated whole body glucose
disposal rate (Rd clamp; P  0.0001) and a 90% increased
nonoxidative glucose metabolism (P  0.0001). Furthermore,
we found a significant positive correlation between 	-GS
activity (insulin-stimulated GS activity  basal GS activity)
and 	-whole body glucose disposal [Rd clamp (glucose dis-
Table 2. Association between proximal insulin signaling and
GS activity
Insulin-Stimulated GS
Activity (FV%)
	-GS Activity
(FV%)
IRTK activity (AU) 1%1 No change
IRS-1-PI3K activity (AU) 3%1 4%1
p-Akt-Thr308 (AU) 9%1* 18%1**
p-Akt-Ser473 (AU) 3%2 8%1
Akt1 activity (AU) No change 1%2
Akt2 activity (AU) 9%1* 19%1**
The statistical model can be written as ln(insulin-stimulated GS activity) 
age  sex  total fat percentage  V˙ O2max  basal glycogen content 
measurement of proximal insulin signaling activity. The regression coefficient
expresses the change in the response variable (e.g., insulin-stimulated GS
activity) associated with a doubling of the explanatory variable (e.g., IRTK
activity) from the average. All measurements of insulin signaling were mea-
sured in insulin-stimulated biopsies. *P  0.05; **P  0.01; 1increased GS
activity; 2decreased GS activity.
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posal during insulin stimulation)  Rd basal (basal glucose
disposal)] (r  0.44, P  0.0001). The effect of age on GS
activity and phosphorylation has been published previously
(33). In this cohort, insulin-stimulated GS activity was not
different in males compared with females [males: 32.6% (SD:
9.3%); females: 32.5% (SD: 9.8%); P  0.82]. In accord with
previous studies, 2 h of insulin stimulation did not result in
elevated intramuscular glycogen levels (Table 1). This likely
reflects that the intraindividual variation is too large to detect
the expected increase in intramuscular glycogen levels of
2–4% during the current study setup (43, 44).
Proximal insulin signaling and GS activity in humans. In-
sulin-stimulated GS activity was significantly associated with
insulin-stimulated levels of p-Akt-Thr308 (P  0.01; Table 2
and Fig. 1A) and Akt2 activity (P  0.04) but not with IRTK,
IRS-1-PI3K, Akt1 activity, or p-Akt-Ser473 (P  0.48 for all
analyses). A doubling of p-Akt-Thr308 or Akt2 activity from
the average was associated with an increase in insulin-stimu-
lated GS activity of 9% (Table 2). Similar results were ob-
tained for 	-GS activity [insulin-stimulated GS activity basal
GS activity; 18 (P 0.003) and 19% (P 0.008) increases for
doublings of p-Akt-Thr308 and Akt2 activity, respectively].
Using simple univariate analyses, Akt2 activity was nega-
tively correlated with p-GS 2  2a (r  0.24, P  0.001),
similarly to p-Akt-Thr308, and was not significantly correlated
with p-GS 3a  3b (r  0.11, P  0.16) or GSK3 activity
(r  0.09, P  0.22). Although Akt2 activity was not signif-
icantly correlated with insulin-stimulated GS activity (r 
0.11, P  0.12), it was significantly correlated with 	-GS
activity (r  0.17, P  0.02), supporting the findings in Table
2, where multiple regression analyses were employed. Since
the study population was very diverse, including males and
females, young and old, lean and obese, physically active and
inactive, etc., the correlation coefficients of these unadjusted
analyses are not very high.
GS phosphorylation in humans. Since only p-Akt-Thr308 and
Akt2 activity were associated with GS activity, only these were
included in further analyses of GS regulation. p-Akt-Thr308
was significantly associated with p-GS 2 2a (P 0.001; Fig.
1B) but not p-GS 3a  3b (P  0.93; Fig. 1C) or GSK-3
activity (P  0.41; Fig. 1D). A doubling of p-Akt-Thr308 was
associated with 26% decreased p-GS2  2a. Similar results
were obtained for Akt2 activity, where a significant association
was found between Akt2 activity and p-GS 2  2a (29%
decreased p-GS2 2a, P 0.001) but not p-GS 3a 3b (P
0.07) and GSK-3 activity (P  0.11).
Insulin decreased p-GS 2  2a [basal: 3.8 (SD: 2.7) arbitrary
units (AU) vs. insulin: 3.1 (SD: 2.0) AU, P 0.001], p-GS 3a
3b [0.26 (SD: 0.19) AU vs. 0.16 (SD: 0.10) AU, P 0.001], and
GSK-3 activity significantly [5.1 (SD: 1.1) vs. 3.6 (SD: 0.9) AU,
P  0.001].
Regulation of GS activity by phosphorylation in humans.
Insulin-stimulated GS activity was negatively associated with
p-GS 2  2a (a doubling of p-GS 2  2a was associated with
12% decreased GS activity, P  0.001; Fig. 1E) but not p-GS
3a  3b (P  0.32; Fig. 1F) or GSK-3 activity (P  0.28).
Similar results for regulation of 	-GS activity by p-GS 2  2a
were demonstrated. Additionally, 	-GS activity was negatively
associated with 	-p-GS 2 2a (P 0.03) but not 	-p-GS 3a
3b (P  0.47).
Regulation of GS activity in mice. EDL muscles from wild-type
and Akt2-KO mice were sampled to validate our results from the
human study. Western blot analyses showed complete loss of
expression of Akt2 in skeletal muscle (P  0.001; Fig. 2A).
Furthermore, both insulin-mediated p-Akt-Thr308 (P  0.003;
Fig. 2B) and p-Akt-Ser473 (P  0.003; Fig. 2C) were reduced
markedly. Employing our transgenic animal model, we confirmed
Akt2’s involvement in insulin-mediated GS activation by demon-
strating that insulin-stimulated GS activity was reduced markedly
in Akt2-KO mice compared with wild-type mice (P  0.05; Fig.
2D and Table 3). Furthermore, the effect of insulin was abolished
completely in Akt2-KO mice (P  0.66; Fig. 2D and Table 3).
Next, we investigated whether Akt2 was necessary for insulin-
mediated GS dephosphorylation in rodent skeletal muscle.
Insulin stimulation resulted in dephosphorylation of sites
3a  3b in wild-type mice (P  0.01; Fig. 2F). This effect
of insulin was not evident in the Akt2-KO mice (P  0.66;
Fig. 2F). However, we observed no effect of insulin on p-GS
2  2a in either the wild-type (P  0.98; Fig. 2E) or
Akt2-KO mice (P  0.53; Fig. 2E).
DISCUSSION
In this study, we found that in humans GS activity was
positively associated with p-Akt-Thr308 and Akt2 activity but not
IRS-1-PI3K activity. Furthermore, p-Akt-Thr308 and Akt2 activity
were negatively associated with p-GS 2  2a, which in turn was
negatively associated with GS activity. In contrast, p-Akt-Thr308
and Akt2 activity were not associated with p-GS 3a  3b or
GSK-3 activity in our human population. Thus, although dephos-
phorylation of sites 3a  3b is necessary for GS activation,
phosphorylation status of sites 2  2a may be critical for “fine-
tuning” GS activity in humans. To validate these results, we
employed a transgenic animal model with whole body Akt2-KO.
We validated that Akt2 indeed is necessary for insulin-mediated
GS activation. However, since p-GS 2 2a was not regulated by
insulin in rodent muscle [in contrast to human muscle (13, 18,
42)], we could not use this model to validate that Akt2 regulates
p-GS 2  2a, as indicated in our cross-sectional human study.
p-Akt-Thr308 and Akt2 activity were the only measures of prox-
imal insulin signaling significantly associated with GS ac-
tivity. Because p-Akt-Thr308 was strongly associated with
Akt2 activity in this study population (9), we hypothesize that
its effect was mediated mainly through Akt2 activation. Pre-
viously, we demonstrated that muscle GS activity was
positively associated with p-Akt-Thr308 but not with IRS-1-
PI3K activity or p-Akt-Ser473 (15, 18). The putative impor-
tance of p-Akt-Thr308 but not p-Akt-Ser473 in the control of GS
activity may seem strange, since both phosphorylations are
needed for full Akt activation and thus probably also for full
Akt-dependent GS activation. Nonetheless, a study has sug-
gested that phosphorylation of residue Ser473 precedes phos-
phorylation of residue Thr308 (36). Thus, it is possible that
extensive regulation of the insulin signal occurs at the level of
p-Akt-Thr308 after phosphorylation of residue Ser473. A weak
association between PI3K and GS activity is supported by
studies demonstrating dissociation between IRS-1-PI3K activ-
ity and GS activity in human participants (5, 19, 42). Although
several studies have provided indirect evidence suggesting that
reduced GS activity in insulin-resistant participants was asso-
ciated with reduced PI3K but normal Akt activity, direct
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Fig. 1. Insulin-stimulated levels of glycogen synthase (GS) fractional activity (A), phosphorylation of sites 2  2a on GS (p-GS 2 2a; B), phosphorylation of
sites 3a 3b on GS (p-GS 3a 3b; C), and GSK-3 activity (D) as a function of phosphorylation of Thr308 on Akt (p-Akt-Thr308). Additionally, insulin-stimulated
levels of GS fractional activity were plotted against insulin-stimulated levels of p-GS 2  2a (E) and p-GS 3a  3b (F). GS phosphorylation was corrected for
total GS protein content. Since the antibodies for total Akt protein and phosphorylation status were not isoform specific, this could not be done for Akt
phosphorylation. Correlation coefficients (Spearman’s rank correlation) and P values for each correlation have been included; n  181 individuals. Each black
dot represents data from 1 twin subject. AU, arbitrary units.
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statistical analyses of the association between GS and PI3K as
well as Akt activity were not performed in those studies (17,
19). It is well established that PI3K activity is necessary for GS
activation (45); however, our study suggests that the signal is
“fine-tuned” at the level of Akt, since only Akt was signifi-
cantly associated with GS activity in this study and insulin-
mediated glucose disposal in our previous study (9). This
indicates strong regulation/modification of the insulin signal at
this level and suggests a role for Akt as a “master switch” in
insulin-dependent GS activation in humans. Finally, we dem-
onstrated the importance of Akt2 over Akt1 in the regulation of
GS, thus supporting studies indicating that Akt2 is the major
Akt isoform involved in glucose metabolism in humans (3, 42).
Uniquely, we were able to confirm the importance of Akt2 in
the regulation of muscle GS activity in our transgenic rodent
study, where loss of Akt2 in skeletal muscle abolished insulin-
mediated GS activation completely. These results elaborate on
the conclusions from an earlier study demonstrating that inhi-
bition of all known Akt isoforms, Akt1, Akt2, and Akt3, in
rodent muscle cells (L6 cells) resulted in decreased insulin-
mediated GS activation (40). Previously, we demonstrated that
reduced p-Akt-Thr308 and Akt2 activity was associated with
insulin resistance in this human study population (9). The
present findings suggest that part of this effect may be medi-
ated through decreased GS activity (33).
Investigating potential mechanisms by which Akt could
regulate GS activity, we found that insulin-stimulated p-Akt-
Thr308 and Akt2 activity were negatively associated with p-GS
2  2a in our human population. Supporting our results,
previous studies have demonstrated that reduced insulin-stim-
ulated p-Akt-Thr308 coincided with reduced dephosphorylation
of sites 2  2a in studies of insulin-resistant human muscle
(15, 18). The mechanistic link between Akt activity and re-
duced p-GS 2  2a is unknown but may involve activation of
phosphatases, including protein phosphatase 1, which is indeed
regulated by insulin (35), or inhibition of kinases responsible
for the phosphorylation of sites 2  2a, including PKA, which
is inhibited by insulin in primates (28). We were not able to
validate the importance of Akt2 for insulin-mediated GS de-
phosphorylation of sites 2  2a in our mouse model, since
p-GS 2  2a was not affected by insulin in this rodent model.
Similarly, insulin appears to not be able to induce dephosphor-
ylation of sites 2  2a in rat skeletal muscle (25). This is in
contrast to insulin’s effect on p-GS 2  2a in humans (13, 18,
42). Low antibody specificity cannot explain our “missing”
effect of insulin on p-GS 2  2a in mice since we have
demonstrated previously that stimulation with AICAR, an
activator of AMPK, results in two- to threefold increased p-GS
2  2a, using the same antibody (22). Thus, it will require
another study model, possibly transgenic human muscle stem
cells, to validate the putative association between Akt2 activity
and dephosphorylation of sites 2 2a in humans. We found no
association between Akt and p-GS 3a 3b in our human study
population, which is in agreement with the lack of association
between Akt and GSK3 activity. Most evidence supporting a
direct role of Akt in the regulation of muscle GSK-3 activity
derives from studies in rodents (2, 27) and rodent cell lines (7),
whereas previous human studies have provided mostly indirect
evidence (15). In line with previous studies (2, 7, 27), using our
unique animal model, we could provide direct evidence for the
involvement of Akt2 in insulin-mediated dephosphorylation of
sites 3a  3b in rodents. In this study we were able to measure
only GSK-3 activity in our human population. Nonetheless, a
study has demonstrated that GSK-3 is the most important
isoform in the regulation of murine GS activity (27). However,
since GSK-3 would mediate its effect through p-GS 3a  3b,
which was not associated with Akt or GS activity in this human
study population, it seems unlikely that GSK-3 would be
strongly associated with Akt or GS activity. Our study is the
first major study to investigate the association between Akt and
GSK-3 activity in humans, and although we cannot rule out an
effect of Akt on GSK-3 activity, our results indeed question the
common perception of Akt primarily acting through GSK-3 in
humans.
In accord with Akt activity being negatively associated with
p-GS 2  2a and positively associated with GS activity in our
human population, we demonstrated that p-GS 2  2a was
strongly negatively associated with GS activity. This is in
accord with previous studies demonstrating that insulin-resis-
tant individuals, including patients with HIV-associated lipo-
dystrophy (15), obesity (18), T2D (18), and polycystic ovary
syndrome (13), displayed both reduced insulin-mediated de-
phosphorylation of sites 2  2a on GS as well as reduced GS
activity. p-GS 3a  3b was not associated with GS activity,
which opposes several studies demonstrating that p-GS 3a 
3b inhibits GS activity in rodents (2, 27, 38). However, in
studies investigating whether p-GS 3a  3b can be linked to
GS activity in human skeletal muscle, this was seen only in
patients with HIV (15) or polycystic ovary syndrome (13) but
not in healthy controls (13, 18). Thus, our results suggest that
insulin-mediated dephosphorylation of sites 3a  3b on GS
may be permissive rather than directly controlling GS activity
in human skeletal muscle from healthy individuals. Although a
permissive role of insulin-mediated dephosphorylation of sites
3a 3b is in contrast to previous rodent and cell model studies
(2, 27, 38), it is important to keep in mind that our study is the
first human study large enough to investigate this in a human
physiologically relevant in vivo setting. The transition from
transgenic animals and rodent cell models to humans might
explain partly the different results regarding the role of p-GS
3a  3b on GS activity, highlighting the need for further
studies of this important aspect of GS activation in human
skeletal muscle. Nonetheless, we acknowledge that our cross-
sectional study design does not permit us to exclude a direct
role for p-GS 3a  3b in the regulation of human GS activity.
Table 3. GS activity in wild-type and whole body Akt2-KO
mice
Wild Type Akt2-KO
Basal Insulin Basal Insulin
GS activity, 0.17
mmol/l G6P
7.9 (0.8) 9.4 (2.2) 8.3 (0.7) 8.7 (1.4)
GS activity, 8.00
mmol/l G6P
16.1 (3.2) 15.1 (3.8) 16.1 (1.9) 16.7 (3.8)
GS activity (FV%) 50 (7) 63 (8)* 51 (3) 53 (8)
Data are means (SD). KO, knockout. GS activity in the presence of 0.17 and
8 mmol/l G6P is given as nmol  min1  mg protein1. Data are paired (basal
and insulin-stimulated samples were from the same animal); n  6 mice in
each group. *P  0.05 vs. basal. P values for this table were calculated using
paired t-tests.
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The regression and correlation analyses of the association
between GS activity and Rd clamp as well as nonoxidative
glucose metabolism indicate that changes in muscle GS activ-
ity may have very large effects on whole body glucose metab-
olism. Our study suggests that Akt2 is not the only major
regulator of GS activity, since a doubling of Akt2 phosphory-
lation/activity was associated with “only” a 10–20% increased
GS activity. In this regard, it is important to keep in mind that
additional signaling mediators, including the kinases AMPK,
PKA, and PKC, are involved in regulating GS activity (6, 17).
Nonetheless, this study implicates Akt2 as a critical node in the
control of GS in human muscle and presents data on the
possible mechanism for this regulation, Akt2-dependent de-
phosphorylation of sites 2  2a on GS.
It could be hypothesized that the timing of biopsy exci-
sion (after 2 h of insulin stimulation) could affect the results
of this study, since the insulin signal might have been
attenuated by this “long-term” insulin stimulation. How-
ever, this is unlikely, since both we and others have dem-
onstrated that IRTK, IRS-1-PI3K, Akt, and GS activity were
not attenuated after 2 h of physiological insulin stimulation
in humans (11, 16, 24, 41, 43, 44).
In conclusion, our results suggest that the association be-
tween proximal insulin signaling and GS activity in healthy
individuals may be mediated primarily through Akt-dependent
regulation of NH2-terminal GS phosphorylation. From this
study we hypothesize that although dephosphorylation of sites
3a and 3b seems to be required for GS activation, it is the
Akt2-dependent dephosphorylation of sites 2  2a that “fine-
tunes” the insulin-mediated activation of GS in humans. None-
theless, additional pathways apart from the canonical insulin
signaling pathway seem to be involved in GS activation.
ACKNOWLEDGMENTS
We thank the study participants. Furthermore, we thank Marianne Modest
and Betina Bolmgren for skilled technical assistance. Finally, we thank
Grahame D. Hardie (Division of Molecular Physiology, University of Dundee,
Dundee, UK) and Oluf Pedersen (University of Copenhagen, Copenhagen,
Denmark) for their kind donation of antibodies against phosphorylated GS and
total GS, respectively.
GRANTS
M. Friedrichsen was supported by a grant from the Danish Agency for
Science Technology and Innovation. This study was supported by grants from
the Danish Medical Research Council, the Danish Strategic Research Council,
the Novo Nordisk Foundation, the Danish Diabetes Association, the Lundbeck
Foundation, The UNIK Project: Food, Fitness, & Pharma for Health and
Disease, supported by the Danish Ministry of Science, Technology, and
Innovation, and an integrated 6th Frame Work EU project (EXGENESIS)
(contract no. LSHM-CT-2004-005272) from the European Union. This work
was supported in part by the National Institutes of Health (R01-AR-42238 to
L. J. Goodyear).
DISCLOSURES
B. F. Hansen is employed at Novo Nordisk. A. Vaag has received a grant
from Novo Nordisk for this research. M. Friedrichsen and A. Vaag are
shareholders at Novo Nordisk.
AUTHOR CONTRIBUTIONS
M.F., H.B.-N., A.V., P.P., and J.F.W. contributed to the conception and
design of the research; M.F., J.B.B., E.A.R, C.P., B.F.H., M.F.H., L.J.G., P.P.,
and J.F.W. performed the experiments; M.F., P.P., and J.F.W. analyzed the
data; M.F., R.R.-M., and J.F.W. interpreted the results of the experiments;
M.F. and J.B.B. prepared the figures; M.F. drafted manuscript; M.F., J.B.B.,
E.A.R., R.R.-M., C.P., B.F.H., H.B.-N., M.F.H., L.J.G., A.V., P.P., and J.F.W.
edited and revised the manuscript; M.F., J.B.B., E.A.R., R.R.-M., C.P., B.F.H.,
H.B.-N., M.F.H., L.J.G., A.V., P.P., and J.F.W. approved the final version of
the manuscript.
REFERENCES
1. Azpiazu I, Manchester J, Skurat AV, Roach PJ, Lawrence JC Jr.
Control of glycogen synthesis is shared between glucose transport and
glycogen synthase in skeletal muscle fibers. Am J Physiol Endocrinol
Metab 278: E234–E243, 2000.
2. Bouskila M, Hirshman MF, Jensen J, Goodyear LJ, Sakamoto K.
Insulin promotes glycogen synthesis in the absence of GSK3 phosphory-
lation in skeletal muscle. Am J Physiol Endocrinol Metab 294: E28–E35,
2008.
3. Bouzakri K, Zachrisson A, Al-Khalili L, Zhang BB, Koistinen HA,
Krook A, Zierath JR. siRNA-based gene silencing reveals specialized
roles of IRS-1/Akt2 and IRS-2/Akt1 in glucose and lipid metabolism in
human skeletal muscle. Cell Metab 4: 89–96, 2006.
4. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB 3rd,
Kaestner KH, Bartolomei MS, Shulman GI, Birnbaum MJ. Insulin
resistance and a diabetes mellitus-like syndrome in mice lacking the
protein kinase Akt2 (PKB beta). Science 292: 1728–1731, 2001.
5. Christ-Roberts CY, Pratipanawatr T, Pratipanawatr W, Berria R,
Belfort R, Kashyap S, Mandarino LJ. Exercise training increases
glycogen synthase activity and GLUT4 expression but not insulin signal-
ing in overweight nondiabetic and type 2 diabetic subjects. Metabolism 53:
1233–1242, 2004.
6. Cohen P, Alessi DR, Cross DA. PDK1, one of the missing links in insulin
signal transduction? FEBS Lett 410: 3–10, 1997.
7. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA.
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein
kinase B. Nature 378: 785–789, 1995.
8. Fisher JS, Nolte LA, Kawanaka K, Han DH, Jones TE, Holloszy JO.
Glucose transport rate and glycogen synthase activity both limit skeletal
muscle glycogen accumulation. Am J Physiol Endocrinol Metab 282:
E1214–E1221, 2002.
9. Friedrichsen M, Poulsen P, Richter EA, Hansen BF, Birk JB, Ribel-
Madsen R, Stender-Petersen K, Nilsson E, Beck-Nielsen H, Vaag A,
Wojtaszewski JF. Differential aetiology and impact of phosphoinositide
3-kinase (PI3K) and Akt signalling in skeletal muscle on in vivo insulin
action. Diabetologia 53: 1998–2007, 2010.
10. Friedrichsen M, Ribel-Madsen R, Wojtaszewski J, Grunnet L, Rich-
ter EA, Billestrup N, Ploug T, Vaag A, Poulsen P. Dissociation between
skeletal muscle inhibitor-kappaB kinase/nuclear factor-kappaB pathway
activity and insulin sensitivity in nondiabetic twins. J Clin Endocrinol
Metab 95: 414–421, 2010.
11. Frosig C, Rose AJ, Treebak JT, Kiens B, Richter EA, Wojtaszewski
JF. Effects of endurance exercise training on insulin signaling in human
skeletal muscle: interactions at the level of phosphatidylinositol 3-kinase,
Akt, and AS160. Diabetes 56: 2093–2102, 2007.
12. Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J,
Bennett PH, Knowler WC. The 1997 American Diabetes Association
and 1999 World Health Organization criteria for hyperglycemia in the
diagnosis and prediction of diabetes. Diabetes Care 23: 1108–1112, 2000.
13. Glintborg D, Højlund K, Andersen NR, Hansen BF, Beck-Nielsen H,
Wojtaszewski JF. Impaired insulin activation and dephosphorylation of
glycogen synthase in skeletal muscle of women with polycystic ovary
syndrome is reversed by pioglitazone treatment. J Clin Endocrinol Metab
93: 3618–3626, 2008.
14. Groop LC, Kankuri M, Schalin-Jäntti C, Ekstrand A, Nikula-Ijäs P,
Widén E, Kuismanen E, Eriksson J, Franssila-Kallunki A, Saloranta
C, Koskimies S. Association between polymorphism of the glycogen
synthase gene and non-insulin-dependent diabetes mellitus. N Engl J Med
328: 10–14, 1993.
15. Haugaard SB, Andersen O, Madsbad S, Frøsig C, Iversen J, Nielsen
JO, Wojtaszewski JF. Skeletal muscle insulin signaling defects down-
stream of phosphatidylinositol 3-kinase at the level of Akt are associated
with impaired nonoxidative glucose disposal in HIV lipodystrophy. Dia-
betes 54: 3474–3483, 2005.
16. Høeg LD, Sjøberg KA, Jeppesen J, Jensen TE, Frøsig C, Birk JB,
Bisiani B, Hiscock N, Pilegaard H, Wojtaszewski JF, Richter EA,
Kiens B. Lipid-induced insulin resistance affects women less than men
and is not accompanied by inflammation or impaired proximal insulin
signaling. Diabetes 60: 64–73, 2011.
E638 SITE 2  2a PHOSPHORYLATION REGULATES GS ACTIVITY
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00494.2012 • www.ajpendo.org
 by 10.220.33.3 on February 5, 2017
http://ajpendo.physiology.org/
D
ow
nloaded from
 
17. Højlund K, Beck-Nielsen H. Impaired glycogen synthase activity and
mitochondrial dysfunction in skeletal muscle: markers or mediators of
insulin resistance in type 2 diabetes? Curr Diabetes Rev 2: 375–395, 2006.
18. Højlund K, Birk JB, Klein DK, Levin K, Rose AJ, Hansen BF, Nielsen
JN, Beck-Nielsen H, Wojtaszewski JF. Dysregulation of glycogen syn-
thase COOH- and NH2-terminal phosphorylation by insulin in obesity and
type 2 diabetes mellitus. J Clin Endocrinol Metab 94: 4547–4556, 2009.
19. Højlund K, Staehr P, Hansen BF, Green KA, Hardie DG, Richter EA,
Beck-Nielsen H, Wojtaszewski JF. Increased phosphorylation of skeletal
muscle glycogen synthase at NH2-terminal sites during physiological
hyperinsulinemia in type 2 diabetes. Diabetes 52: 1393–1402, 2003.
20. Højlund K, Wojtaszewski JF, Birk J, Hansen BF, Vestergaard H,
Beck-Nielsen H. Partial rescue of in vivo insulin signalling in skeletal
muscle by impaired insulin clearance in heterozygous carriers of a muta-
tion in the insulin receptor gene. Diabetologia 49: 1827–1837, 2006.
21. Jensen J, Jebens E, Brennesvik EO, Ruzzin J, Soos MA, Engebretsen
EM, O’Rahilly S, Whitehead JP. Muscle glycogen inharmoniously
regulates glycogen synthase activity, glucose uptake, and proximal insulin
signaling. Am J Physiol Endocrinol Metab 290: E154–E162, 2006.
22. Jorgensen SB, Nielsen JN, Birk JB, Olsen GS, Viollet B, Andreelli F,
Schjerling P, Vaulont S, Hardie DG, Hansen BF, Richter EA, Woj-
taszewski JF. The alpha2–5=AMP-activated protein kinase is a site 2
glycogen synthase kinase in skeletal muscle and is responsive to glucose
loading. Diabetes 53: 3074–3081, 2004.
23. Jucker BM, Barucci N, Shulman GI. Metabolic control analysis of
insulin-stimulated glucose disposal in rat skeletal muscle. Am J Physiol
Endocrinol Metab 277: E505–E512, 1999.
24. Kim YB, Nikoulina SE, Ciaraldi TP, Henry RR, Kahn BB. Normal
insulin-dependent activation of Akt/protein kinase B, with diminished
activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J
Clin Invest 104: 733–741, 1999.
25. Lai YC, Zarrinpashneh E, Jensen J. Additive effect of contraction and
insulin on glucose uptake and glycogen synthase in muscle with different
glycogen contents. J Appl Physiol 108: 1106–1115, 2010.
26. Lawrence JC Jr, Roach PJ. New insights into the role and mechanism of
glycogen synthase activation by insulin. Diabetes 46: 541–547, 1997.
27. McManus EJ, Sakamoto K, Armit LJ, Ronaldson L, Shpiro N,
Marquez R, Alessi DR. Role that phosphorylation of GSK3 plays in
insulin and Wnt signalling defined by knockin analysis. EMBO J 24:
1571–1583, 2005.
28. Ortmeyer HK. Insulin decreases skeletal muscle cAMP-dependent pro-
tein kinase (PKA) activity in normal monkeys and increases PKA activity
in insulin-resistant rhesus monkeys. J Basic Clin Physiol Pharmacol 8:
223–235, 1997.
29. Perseghin G, Price TB, Petersen KF, Roden M, Cline GW, Gerow K,
Rothman DL, Shulman GI. Increased glucose transport-phosphorylation
and muscle glycogen synthesis after exercise training in insulin-resistant
subjects. N Engl J Med 335: 1357–1362, 1996.
30. Poulsen P, Levin K, Beck-Nielsen H, Vaag A. Age-dependent impact of
zygosity and birth weight on insulin secretion and insulin action in twins.
Diabetologia 45: 1649–1657, 2002.
31. Poulsen P, Levin K, Petersen I, Christensen K, Beck-Nielsen H, Vaag
A. Heritability of insulin secretion, peripheral and hepatic insulin action,
and intracellular glucose partitioning in young and old Danish twins.
Diabetes 54: 275–283, 2005.
32. Poulsen P, Vaag A. The intrauterine environment as reflected by birth size
and twin and zygosity status influences insulin action and intracellular
glucose metabolism in an age- or time-dependent manner. Diabetes 55:
1819–1825, 2006.
33. Poulsen P, Wojtaszewski JF, Petersen I, Christensen K, Richter EA,
Beck-Nielsen H, Vaag A. Impact of genetic versus environmental factors
on the control of muscle glycogen synthase activation in twins. Diabetes
54: 1289–1296, 2005.
34. Rothman DL, Shulman RG, Shulman GI. 31P nuclear magnetic reso-
nance measurements of muscle glucose-6-phosphate. Evidence for re-
duced insulin-dependent muscle glucose transport or phosphorylation
activity in non-insulin-dependent diabetes mellitus. J Clin Invest 89:
1069–1075, 1992.
35. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and
lipid metabolism. Nature 414: 799–806, 2001.
36. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and
regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098–
1101, 2005.
37. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman
RG. Quantitation of muscle glycogen synthesis in normal subjects and
subjects with non-insulin-dependent diabetes by 13C nuclear magnetic
resonance spectroscopy. N Engl J Med 322: 223–228, 1990.
38. Skurat AV, Dietrich AD, Roach PJ. Glycogen synthase sensitivity to
insulin and glucose-6-phosphate is mediated by both NH2- and COOH-
terminal phosphorylation sites. Diabetes 49: 1096–1100, 2000.
39. Szendroedi J, Schmid AI, Chmelik M, Toth C, Brehm A, Krssak M,
Nowotny P, Wolzt M, Waldhausl W, Roden M. Muscle mitochondrial
ATP synthesis and glucose transport/phosphorylation in type 2 diabetes.
PLoS Med 4: e154, 2007.
40. Takata M, Ogawa W, Kitamura T, Hino Y, Kuroda S, Kotani K, Klip
A, Gingras AC, Sonenberg N, Kasuga M. Requirement for Akt (protein
kinase B) in insulin-induced activation of glycogen synthase and phos-
phorylation of 4E-BP1 (PHAS-1). J Biol Chem 274: 20611–20618, 1999.
41. Thong FS, Derave W, Kiens B, Graham TE, Ursø B, Wojtaszewski JF,
Hansen BF, Richter EA. Caffeine-induced impairment of insulin action
but not insulin signaling in human skeletal muscle is reduced by exercise.
Diabetes 51: 583–590, 2002.
42. Vind BF, Birk JB, Vienberg SG, Andersen B, Beck-Nielsen H, Woj-
taszewski JF, Højlund K. Hyperglycaemia normalises insulin action on
glucose metabolism but not the impaired activation of AKT and glycogen
synthase in the skeletal muscle of patients with type 2 diabetes. Diabeto-
logia 55: 1435–1445, 2012.
43. Wojtaszewski JF, Hansen BF, Gade, Kiens B, Markuns JF, Goodyear
LJ, Richter EA. Insulin signaling and insulin sensitivity after exercise in
human skeletal muscle. Diabetes 49: 325–331, 2000.
44. Wojtaszewski JF, Hansen BF, Kiens B, Richter EA. Insulin signaling in
human skeletal muscle: time course and effect of exercise. Diabetes 46:
1775–1781, 1997.
45. Wojtaszewski JF, Lynge J, Jakobsen AB, Goodyear LJ, Richter EA.
Differential regulation of MAP kinase by contraction and insulin in
skeletal muscle: metabolic implications. Am J Physiol Endocrinol Metab
277: E724–E732, 1999.
E639SITE 2  2a PHOSPHORYLATION REGULATES GS ACTIVITY
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00494.2012 • www.ajpendo.org
 by 10.220.33.3 on February 5, 2017
http://ajpendo.physiology.org/
D
ow
nloaded from
 
